PRVL Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice.
Quick AnswerPRVL — AI-powered stock analysis.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
PRVL (PRVL) Healthcare & Pipeline Overview
Who Are PRVL's Competitors?
PRVL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NVO Novo Nordisk A/S | $41.63 | +2.41% | $184B | 86 5-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $538.60 | -0.74% | $137B | 94 5-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $955.47 | +0.45% | $98.8B | 94 5-pillar |
| ARGX argenx SE | $960.04 | -2.17% | $60.4B | 96 5-pillar |
| GMAB Genmab A/S | $51.37 | -0.72% | $31.7B | 68 5-pillar |
| RPRX Royalty Pharma plc | $69.31 | +0.84% | $30.9B | 73 5-pillar |
| UTHR United Therapeutics Corporation | $591.17 | -0.36% | $25.2B | 97 5-pillar |
| INCY Incyte Corporation | $120.97 | -0.60% | $24.7B | 96 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are the Key Risks for PRVL?
Negative return on equity (-38.2%) — the business is not currently generating profit on shareholder capital.
Key Financial Metrics
Return on equity for PRVL stands at -38.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.8%, showing how much profit it generates from its asset base. A current ratio of 14.74 indicates the company holds enough short-term assets to cover its near-term obligations.
PRVL Latest News
No recent news available for PRVL.
PRVL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PRVL.
Price Targets
Wall Street price target analysis for PRVL.
PRVL MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PRVL; grades run from A+ (80-100) to F (below 30).
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.